Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system

Abstract

The purpose of the present investigation was to prepare matrix tablets of naproxen using a hydrophobic polymer, i.e., Eudragit RLPO, RSPO, and combination of both, by wet granulation method. The tablets were further coated with different concentrations of Eudragit S-100, a pH-sensitive polymer, by dip immerse method. In vitro drug release studies of tablets were carried out in different dissolution media, i.e., 0.1 N HCl (pH 1.2), phosphate buffers pH 6.8 and 7.4, with or without rat cecal content. The swelling studies of the optimized formulation were carried out. The physicochemical parameters of all the formulations were found to be in compliance with the pharmacopoeial standards. The effect of dissolution medium on the surface of matrix tablet was determined by using Scanning Electron Microscopy technique. The stability studies of all formulations were performed as per ICH guidelines. The results demonstrated that the tablets coated with Eudragit S-100 (2% w/v) showed a sustained release of 94.67% for 24 h, but drug release increased to about 98.60% for 24 h in the presence of rat cecal content while the uncoated tablets released the drug within 5 h. With regard to release kinetics, the data were best fitted with the Higuchi model with non-Fickian drug release kinetics mechanism. The stability studies of tablets showed less degradation during accelerated and room temperature storage conditions for 6 months. The enteric-coated Eudragit S-100 coated matrix tablets of naproxen showed promising site-specific drug delivery in the colon region.

Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics

“…This polymer is chemically stable and has excellent extrudability. Furthermore, it is insoluble in water and shows pH-independent swelling properties, being highly permeable, as described above [ 35 , 36 ].…”

In situ Formed Implants, Based on PLGA and Eudragit Blends, for Novel Florfenicol Controlled Release Formulations

“…40 On the other hand, EuS100 peaks are observed: 2950, 1730 and 1450 cm À1 due to carboxylic oxydryl, ester and methyl groups, respectively. 41 Black arrows indicate shifts from 1780-1730 to 1760 cm À1 which can be associated to polymers interactions related to the blend formation.…”

Study of a delayed-release system for hard and soft capsules coated with eudragit® s100 acrylic polymers

“…The results demonstrated that tablets coated with Eudragit ® S100 (2% w/v) showed controlled release for 24 hours and that this was a promising formulation for specific release in the colon region. Release of the active ingredient from pharmaceutical forms coated with Eudragit ® depends on the pH of the dissolution medium and the coating thickness (Mehta, Chawla, Sharma, & Pawar, 2013).…”